| MEMBRANE TRAFFICKING FACTORS
Correct protein localization to the various intracellular compartments is of critical importance to the proper functioning of a cell. This process, referred to as membrane traffic, requires numerous proteins and complexes to ensure that the organellar proteins are sorted in an appropriate spatiotemporal manner. Defects in this process can result in a variety of human disorders. 1, 2 The process starts with the collection of cargo at regions of the donor compartment that deform to generate a transport carrier. Membrane deformation is achieved by the actions of a complex of proteins referred to as coat proteins. In the early biosynthetic pathway, the coat protein complex called COP II participates in the formation of vesicles from the endoplasmic reticulum (ER), 3 while the coat protein complex coatomer/COP I functions at the level of the Golgi. 4 Recruitment of these complexes to their respective membranes is mediated by the activation of small GTP-binding proteins of the Rab family called Sar1 (which recruits COP II) and Arf1 (which recruits COP I). 5 The carriers also contain membrane proteins of the Soluble NSF Attachment protein REceptor (SNARE) family that are intimately involved in the fusion of the carrier with the target membrane. Once uncoated, the SNARE proteins on the carrier and target membrane interact such that a trans-SNARE complex is formed, consisting of three Q-SNAREs and one R-SNARE. 6 Zippering of the so-called SNARE-domain proximal to the membrane-spanning domain provides the energy to drive membrane fusion. 7, 8 Although originally proposed to provide specificity in carrier-target membrane recognition, 9 it is unlikely that SNAREs alone impart this specificity, and other proteins such as Rabs and tethers/tethering factors have been implicated.
Tethering factors are proteins that are thought to participate in the initial contact between the carrier and the target membrane.
These factors have been divided into two classes: coiled-coil tethering factors and multisubunit tethering factors. 10, 11 The coiled-coil proteins contain heptad repeats allowing for the formation of amphipathic helices that interact with other such proteins to form a relatively strong tether that can bridge two membranes. The multisubunit tethering factors are heteromeric protein complexes that participate in some aspect of tethering the apposed membranes prior to fusion. These complexes function at virtually all organelles of the biosynthetic pathway 11 ( Table 1) .
| THE TRAPP FAMILY OF MULTISUBUNIT TETHERING FACTORS
The aforementioned complexes were originally believed to physically tether apposing membranes. However, this has in fact only been shown to be the case for the HOPS complex. 12 While these com-
plexes may yet be shown to act as tethers, it remains possible that their role in the tethering process is indirect. Thus, understanding the precise function(s) of these complexes is a crucial area for future research.
One well-studied multisubunit tethering factor is the TRAnsport Protein Particle (TRAPP) family of complexes, first identified in yeast.
While initially thought to be a single complex composed of 10 subunits, 13 it became apparent that there were in fact three related complexes, each containing a common core of proteins 14, 15 ( Figure 1A ). The yeast TRAPP I complex is composed of the subunits Trs20, Bet5, two copies of Bet3, Trs23, Trs31 and Trs33. These subunits represent the core of all three TRAPP complexes and are the only proteins in TRAPP I. The TRAPP II and III complexes contain the core with four additional subunits (Tca17, Trs65, Trs120 and Trs130) 132 May have a role in ER-to-Golgi traffic 132, 133 ; functions of individual proteins of the complex are varied 134 
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Cis and medial Golgi, tips and rims of Golgi cisternae, cis and trans Golgi networks, COPI vesicles 157, 158 ; Schindler et al in TRAPP II, and one additional subunit (Trs85) in TRAPP III. 16 All of the yeast subunits are conserved in higher eukaryotes including humans (Table 2) , while humans and other metazoa contain additional associated proteins for which no Saccharomyces cerevisiae homologue has been identified. 17 Curiously, a TRAPP I-equivalent complex is yet to be reported in humans, although human TRAPP II and III complexes have been described. 18, 19 The human complexes contain a similar core of proteins (TRAPPC1, TRAPPC2, two copies of TRAPPC3, TRAPPC4,   TRAPPC5 and TRAPPC6 ). In addition to this core, TRAPP II also contains TRAPPC9 and TRAPPC10, while TRAPP III contains the core with TRAPPC8, TRAPPC11, TRAPPC12 and TRAPPC13 ( Figure 1B ).
Several studies have implicated the TRAPP complexes in the tethering process. 15, 20, 21 It is noteworthy that their role as bona fide
tethers has yet to be definitively demonstrated because these studies relied largely on crude biochemical fractions, genetics and microcopy phenotypes. Indeed, their contribution to this process awaits studies with purified proteins and membranes, and TRAPP complexes may yet be revealed to function indirectly in this process. As yeast TRAPP complexes were shown to bind to the small GTPase Ypt1p in its nucleotide-free state, 22 it was speculated that TRAPP could act as a guanine nucleotide exchange factor (GEF) for this GTPase, converting it to its active form. Indeed, all three TRAPP complexes have been reported to have GEF activity toward Ypt1p, 14, 22, 23 and more recently the TRAPP II complex was shown to have robust GEF activity toward Ypt31 and the related GTPase Ypt32. 24 The GEF activity of recombinant TRAPP I was shown to be dependent upon all of the core proteins except for Trs33 and Trs20. 25 A subsequent study revealed the mechanism for this activity and the key role that the carboxy-terminus of Bet3 plays in destabilizing the GDP nucleotide bound to the GTPase. 26 Consistent with one study in yeast that demonstrated Ypt1
GEF activity for TRAPP II, 26 Yamasaki et al 27 The yeast and human TRAPP complexes. Cartoons of the three yeast complexes (A) and the two known mammalian complexes (B) are shown. The core of proteins found in all complexes is colored in cyan. The arrangement of the subunits within this core is based on its known organization. 25, 26 The placement of Trs85 in yeast TRAPP III is based on biochemical and single-particle electron microscopic data. 14, 41 The placement of Trs130 and Trs120 is based on genetic, mutational and yeast two-hybrid data. 34, 36, 57, 236 It should be noted that the single-particle electron microscopic data suggests the opposite arrangement, 37 a discrepancy that still needs to be resolved.
In the mammalian cartoons, the placement of TRAPPC8 is based on the homology to the yeast protein as well as one study indicating that it interacts with TRAPPC2. 43 The placement of TRAPPC10 is based on a study 65 that suggests it interacts with TRAPPC2L, and the placement of TRAPPC9 is based on a biochemical study 43 Bet5  TRAPPC1  33/54   Trs20  TRAPPC2  34/52   Tca17  TRAPPC2L  24/43   Bet3  TRAPPC3, C3L  56/76, 51/73   Trs23  TRAPPC4  29/44   Trs31  TRAPPC5  31/52   Trs33  TRAPPC6A,B  35/51, 33/47   Trs65   a   Trs85  TRAPPC8  28/49   Trs120  TRAPPC9  25/44   Trs130  TRAPPC10  24/45 TRAPPC11 -
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a Kluyveromyces lactis and Candida glabrata homologues share homology (31% identity/45% similarity) over a relatively small region with TRAPPC13 as revealed by PSI-BLAST. 34 In yeast TRAPP II, variants in trs130 were implicated in antero- The human protein, going by the names sedlin, SEDL, TRAPPC2 and hTrs20, can functionally replace its yeast homologue, 47 suggesting an evolutionarily conserved function for the protein. Consistent with its conserved function, TRAPPC2 was shown to be required for the association of both TRAPPC8 and TRAPPC9 with the human TRAPP complex. 43 The crystal structure of TRAPPC2 was solved and shown to resemble that of the amino-terminal regulatory domain of the SNARE proteins Sec22 and Ykt6. 48 This similarity led to the suggestion that TRAPPC2 either regulated the function of SNARE proteins and/or acted as a protein adaptor, both of which have been supported by subsequent studies in yeast and higher eukaryotes. [41] [42] [43] The overall fold of TRAPPC2 and the regulatory domain of these SNARE proteins have been referred to as longin-domain folds which are found in many trafficking proteins. 49 Interestingly, several other TRAPP core proteins also adopt a three-dimensional structure similar to that of TRAPPC2. 25 A study that elucidated the architecture of the core pro- Emergence of a vesicle at the ER is dependent upon the activity of the GTPase Sar1. 55 TRAPPC2 enhances the inactivation of Sar1 at ER exit sites, 54 thereby preventing membrane constriction and allowing nascent vesicles to grow to a size sufficient to accommodate the large procollagen fibrils. Interestingly, TRAPPC2 is recruited specifically to the sites of procollagen export via an interaction with the procollagen receptor TANGO1.
Although its inclusion as a TRAPP component was originally inferred by analogy to its yeast homologue Trs20, TRAPPC2 was
shown to be present in a high-molecular-weight fraction of a size exclusion column. 56 Subsequent studies showed that the protein To date, all individuals with TRAPPC2 variants suffer from SEDT.
However, no other TRAPP gene variant has been linked to SEDT or any similar type of skeletal defect. These facts suggest that either TRAPPC2 has a unique role within TRAPP complexes, or variants in this small protein affect a non-TRAPP function of TRAPPC2. As deposition of collagen is required for bone development, the specific role of TRAPPC2 in collagen trafficking (discussed above) is a likely explanation for its role in SEDT.
| TRAPPC2L (MIM 610970)
The TRAPPC2L protein was initially identified using a bioinformatics approach as a protein related to TRAPPC2. 57 A multiple sequence alignment demonstrated that only two residues are conserved between these two proteins-Leu36 and Asp37 (TRAPPC2L numbering). Using tandem affinity purification-tagged TRAPPC2L and TRAPPC2, it was shown that both of these proteins are components of the same TRAPP complex(es). Although the three-dimensional structure of TRAPPC2L is yet to be solved, it can be modeled on its yeast homologue called Tca17 64 ( Figure 2 ). Consistent with its primary structural similarities to TRAPPC2 and its yeast homologue Trs20,
Tca17 also adopts a longin-domain fold composed of a central fivestranded β-sheet flanked by three α-helices. The only two residues conserved between TRAPPC2L and TRAPPC2 are predicted to be exposed at the surface of TRAPPC2L, suggesting it too may act as an adaptor protein for other TRAPP subunits, a notion that appears to be supported (see below).
A portion of some TRAPP proteins co-fractionated with TRAPPC2L on membranes of relatively low density on a density gradient while a second pool was found to fractionate at a higher density. 57 While the denser membranes co-fractionated with Golgi markers, the lighter membrane fraction containing TRAPPC2L partially overlapped with a marker for early endosomes, suggesting that TRAPP complexes containing TRAPPC2L may function in a post-Golgi compartment.
Recently, individuals were identified with homozygous variants in TRAPPC2L. 65 Interestingly, the individuals were found to have a missense variant of the conserved Asp37 residue (p.Asp37Tyr). As stated above, the identical variant in TRAPPC2 results in the skeletal defect SEDT. In contrast, the TRAPPC2L individuals harboring this variant suffer from a global developmental delay, microcephaly, dystonia, tetraplegia, rhabdomyolysis, encephalopathy and epilepsy. The p.
Asp37Tyr variant and the equivalent yeast variant (Tca17 Asp45Tyr) both interfere with the interaction between TRAPPC2L and
TRAPPC10 (Trs130 in yeast). Although a TRAPPC2L knockdown in
HeLa cells results in a fragmentation of the Golgi, 57 fibroblasts derived from the individuals with TRAPPC2L variants did not display an abnormal Golgi morphology. 65 These fibroblasts had defects in the trafficking of Golgi marker proteins and also displayed a defect in the exit of a marker protein from the Golgi. Interestingly, GFP-tagged
The location of the conserved leucine and aspartic acid residues on TRAPPC2 and TRAPPC2L. A, TRAPPC2L was modeled using the structure of its yeast homologue Tca17 (PDB ID: 3PR6). The highly similar structure of TRAPPC2 (PDB ID: 1H3Q) is shown on the right for comparison. The location of alpha helix α1, where the only two conserved residues between the two proteins are found, is indicated. B, A close-up view of the overlay of helices α1 from TRAPPC2L and TRAPPC2 with the conserved leucine and aspartic acid residues is shown. The side chains are oriented similarly. Note that helix α1 is not involved in the interaction between TRAPPC2 and other TRAPP subunits of the core complex. The ribbons are colored as in panel A Rab11 localization was altered, with larger and/or more abundant GFP-Rab11 punctae. In addition, there was an increased level of the active (GTP-bound) form of Rab11. This suggests that TRAPPC2L
either negatively regulates the GEF activity of TRAPP for Rab11, or it participates in the recruitment of a Rab11 GAP. The recruitment of a GAP by a TRAPP complex was recently demonstrated in yeast. 66 Rab11 has yet to be shown. Given the large number of effector proteins for Rab11, 68 it remains to be seen how overactivation of this
GTPase results in the clinical pathology of these individuals. As a potential clue, a defect in ciliogenesis and cilia length was noted in the fibroblasts from these individuals, consistent with the link between TRAPP, Rab11 and cilia. 69 
| TRAPPC6A (MIM 610396)
Three isoforms of the TRAPPC6 protein have been described in humans. These include TRAPPC6A1, TRAPPC6A2 and TRAPPC6B.
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TRAPPC6A1 and TRAPPC6B are encoded by different genes and share 56% identity and 72% similarity, while TRAPPC6A2 contains an additional, internal 14 amino acid stretch compared to TRAPPC6A1.
In light of this difference, TRAPPC6A1 has also been referred to in more recent literature as TRAPPC6AΔ. 71, 72 In yeast, the TRAPPC6
homologue Trs33 has been implicated in assembly of the TRAPP II complex via an interaction with the TRAPP II-specific subunit Trs120.
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TRAPPC6A was implicated in pigmentation in a mosaic hypopigmentation (mhyp) mouse in which a provirus randomly inserted into the intron immediately following exon 1 of the gene. 73 The authors suggested that TRAPPC6A is involved in the biogenesis of melanosomes. It is noteworthy that the expression of the TRAPPC6A gene was nearly completely turned off in this mouse. Given that the gene likely shares a promoter in a head-to-head fashion with its neighboring gene BLOC1S3 whose product is implicated in melanosome biogenesis and hypopigmentation, 74 reduced expression of BLOC1S3
would also be expected in the mhyp mouse calling into question the role of TRAPPC6A in pigmentation.
The crystal structure of TRAPPC6A1 was solved in a heterodimeric complex with its TRAPP binding partner TRAPPC3. 75 Remarkably, although these two proteins share little sequence identity, the overall folds of the two proteins were strikingly similar with both proteins composed of a mixed α/β-fold containing four α-helices and four β-strands forming an antiparallel β-sheet. One notable difference between these proteins is the absence of a hydrophobic tunnel in TRAPPC6A1 that was seen in the TRAPPC3 crystal structure.
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TRAPPC6A1 was recently found in extracellular plaques from the brain cortex of individuals with Alzheimer's disease (AD). 71 These plaques were also reactive with an antibody that recognizes 78 The variant was one of five homozygous variants detected in these individuals, all of which are rare and predicted to be pathogenic. While some of the clinical features are similar to those of individuals harboring other TRAPP gene variants (see Table 3 ), it is unclear if the clinical features in these individuals are due to the TRAPPC6A2 variant, one of the other variants or some combination of the five variants.
| TRAPPC6B (MIM 610397)
The structure of TRAPPC6B was solved both as a homodimer 79 and a heterodimer in a complex with TRAPPC3. 80 Not unexpectedly, the TRAPPC6A1-TRAPPC3 and TRAPPC6B-TRAPPC3 heterodimers are nearly the same, although the TRAPPC6A1-containing heterodimer occupies a larger surface area of TRAPPC3 than does the one containing TRAPPC6B. A small stretch of non-conserved amino acids maps to the surface of each heterodimer, suggesting that the heterodimers may interact with different proteins although tissue-specific expression was not seen for either of the isoforms in mouse tissue. 80 Both heterodimers formed a heterotrimeric complex with TRAPPC1, 25, 80 suggesting they can interact with other TRAPP proteins to form iso- and TRAPPC2L, 17 as well as in a high-molecular-weight complex.
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TRAPPC9 is thought to be a component of a TRAPPC10-containing complex. 18 However, while TRAPPC9 was implicated in ER-derived COP II vesicle dynamics, 84 TRAPPC10 depletion did not affect this membrane trafficking step. 27 A TRAPPC9-containing complex bound to Rab18 in its nucleotide-free form and was shown to have GEF activity for this Rab. 28 The authors further demonstrated that deletion of either TRAPPC9 or both TRAPPC9 and TRAPPC10 did not affect membrane traffic but resulted in the appearance of lipid droplets.
TRAPPC9 (called NIBP) was detected in a yeast two-hybrid screen as an interacting partner of the signaling kinase NIK, and was also found to interact with the β-subunit of the kinase IKK (IKKβ), 85 both of which function in the Nuclear Factor -kappa B (NF-κB) signaling pathway. Subsequently, a number of studies have implicated TRAPPC9/ NIBP in NF-κB signaling, with a possible role in cancer metastasis. [86] [87] [88] [89] Although the structure of TRAPPC9 is not known, several studies have addressed aspects of its structure. The amino-terminal portion of the protein (amino acids 117-411) is predicted to adopt an α-solenoid structure with multiple tetratricopeptide repeat (TPR) domains. 90 Such repeats are known to be involved in protein-protein interactions. 91 The carboxy portion of the protein is predicted to contain two ASPM, SPD-2, Hydin (ASH) domains, 90 believed to target proteins to the cilium. 92 A computational model of TRAPPC9 was built using a conserved metalloprotein from Bacillus cereus. 93 Although largely helical, which would be consistent with the predicted TPR and ASH domains, the modeled structure was not reported to have these domains.
A number of variants in TRAPPC9 have now been reported (Table 3) . With the exception of a single report where the affected individual had bigenic TRAPPC9 and PDE3A variants, 94 all individuals with biallelic variants in TRAPPC9 have a strikingly common pathology.
These individuals all display NS-ARID and postnatal microcephaly.
Most are reported to have minimal to no speech and behavioral problems. Some individuals also display abnormalities in the brain such as thinning of the corpus callosum, reduced white matter volume and myelination defects. In addition to these individuals, an individual with a larger homozygous deletion on chromosome 8 encompassing only the TRAPPC9/NIBP gene was reported, with a phenotype similar to those with TRAPPC9 variants. 95 Another individual, identified by homozygosity mapping, had a form of autosomal recessive mental retardation that mapped to the TRAPPC9 gene on chromosome 8.
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Although a number of genes have been linked to NS-ARID,
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TRAPPC9 is unique in that it is the only gene that has been linked to this disorder in more than five families. 93, 97 There are several reasons that support the notion that dysregulation of the NF-κB pathway may be a contributing factor in the pathology of individuals with TRAPPC9
variants. First, there is a growing amount of literature on the involvement of TRAPPC9 in the NF-κB signaling pathway. [85] [86] [87] [88] [89] 98 Second, this pathway is documented to be important for brain function and development. 99, 100 Third, while TRAPPC9 is expressed in a variety of tissues, with the highest being muscle, there is a significant level of the transcript in brain. 85 Fourth, another gene implicated in NS-ARID also impacts NF-κB signaling. 101 Thus, it is tempting to speculate that variants in TRAPPC9 affect the NF-κB pathway leading to NS-ARID.
However, as detailed below, variants in other TRAPP proteins share some of these clinical features, particularly intellectual disability, brain abnormalities and microcephaly. It is possible that there is a wide range of levels of intellectual disability in individuals with TRAPP gene variants and, indeed, there is a rather large spectrum of intellectual disabilities in general. As one of the striking features of TRAPPC9 depletion is an increase in lipid droplet formation, 28 it is unclear how this links to NF-κB signaling and intellectual disability.
| TRAPPC11 (MIM 614138)
In an effort to address whether TRAPPC2 and TRAPPC2L associate with different components of TRAPP, each was appended to a tandem affinity purification tag and purified from HeLa cell lysates. 17 In addition to identifying proteins that were homologous to known yeast TRAPP subunits (see Table 2 ), several additional proteins were identified. One of these proteins was called TRAPPC11 (also called c4orf41). The protein is 1133 amino acids in length and does not have a recognizable homologue in the yeasts S. cerevisiae and Schizosaccharomyces pombe but is found in metazoans. Like other TRAPPassociated proteins, depletion of the protein by RNA interference resulted in a fragmented Golgi. 17 In addition, depletion of the protein arrested a marker protein that normally traverses the secretory pathway in a pre-Golgi compartment that was suggested to be either the ERGIC or ER exit sites. The latter result is consistent with a recent study that suggested a role for TRAPPC12, a protein found in the same TRAPP complex as TRAPPC11, in recruitment of the outer layer of the COP II coat to the ER. 19 In another study employing a different marker protein, ER exit was unaffected and the marker protein was arrested in the Golgi, 102 suggesting TRAPPC11 may function in more than one step of membrane trafficking. Depletion of the Drosophila melanogaster TRAPPC11 homologue, called gryzun, 103 was shown to alter the localization of a cell-surface marker, suggesting a defect in Golgi function. 102 The Danio rerio homologue of TRAPPC11 was found in a zebrafish genetic screen aiming to identify genes involved in liver disease. 104 Indeed, owing to the hepatomegaly seen in the zebrafish TRAPPC11 mutant, the gene was referred to as foie gras (fgr). Closer inspection revealed that the livers in the fgr mutant zebrafish accumulated a substantial amount of lipids.
Although the three-dimensional structure of TRAPPC11 has not been solved, the protein has a region of high conservation that has been referred to as the foie gras domain. Bioinformatic analysis reveals that this domain harbors several regions that may assume a TPR structure. In addition, the protein also has a carboxy-terminal gryzun domain whose function remains unknown.
A recent study implicated human and zebrafish TRAPPC11, to the exclusion of other TRAPP proteins, in N-linked glycosylation. 105 The with TRAPPC11 variants that also suffered from CMD and further broadened the phenotype to include achalasia, alacrima and scoliosis. 109 Siblings with compound heterozygous TRAPPC11 variants (p.
Gln777Pro and p.Phe173Tyrfs13*) and a phenotype similar to those reported by Liang et al 108 were recently reported. 110 In addition to CMD, these latter individuals were also observed to have abnormal dystroglycan staining. The first documented case of a TRAPPC11 variant resulting in an α-dystroglycanopathy was recently reported. , and POMGNT2 to name a few. 116 Finally, TRAPPC11 has been implicated in autophagy 44 (D. Stanga and M. Sacher, unpublished data), and this process is involved in several forms of muscular dystrophy. 117 Thus, with TRAPPC11 functioning in several different cellular Most variants fall within and near the foie gras domain and near the carboxy-terminus, suggesting important functions for these regions of the protein processes, identifying how it results in muscle, eye and brain pathologies will require further dissection of its functions and the use of alternative model systems to study muscle biology.
| TRAPPC12 (MIM: 617669)
Another complex-specific protein is TRAPPC12 (also known as TTC15, TRAMM and CGI-87). This protein is found in metazoa but does not have a recognizable homologue in yeast. It was first identified in a human autophagy proteomic study 44 and subsequently characterized as a component of the human TRAPP complex. 17 It was suggested to be a component of the human TRAPP III complex by virtue of its co-purification with TRAPPC8, but not with TRAPPC9 or TRAPPC10 18 (see Figure 1 ).
Although the structure of TRAPPC12 is yet to be solved, the primary protein sequence indicates the existence of four conserved TPR motifs localized close to its carboxy-terminus that likely facilitate its interaction with other proteins. 91 Within the amino-terminal~200
amino acids there is a region that was shown to be phosphorylated, [118] [119] [120] and some of these phosphoresidues appear to regulate the function of the protein. 121 Immunofluorescence experiments revealed that the protein is distributed as punctae mainly in the cytoplasm and on ER exit sites, and partially co-localizes with the Golgi. 17, 19, 121 Furthermore, traces of the stained protein were also visible in the nucleus, a finding confirmed by subcellular fractionation, biochemical techniques and fluorescence microscopy.
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The TRAPPC12 protein was demonstrated to be involved in ERto-Golgi transport, the regulation of Golgi integrity and autophagy. 17, 44, 122 More recently, a function for the protein in mitosis was also revealed. 121 Depletion of TRAPPC12, but not of any other TRAPP-associated protein, resulted in a significant increase in the mitotic index due to a defect in chromosome congression and activation of the spindle assembly checkpoint. TRAPPC12 associated with metaphase chromosomes and weakly localized to their kinetochores where it was shown to be involved in the recruitment of several kinetochore proteins, most dramatically that of CENP-E. Size exclusion chromatography demonstrated that during mitosis TRAPPC12 was phosphorylated and no longer co-fractionated with the TRAPP complex. The role of TRAPPC12 in mitosis is likely conserved because an association of chicken TRAPPC12 with mitotic chromosomes was also reported. 123 Recently, three individuals from two unrelated families harboring two different TRAPPC12 variants were reported. 124 (Table 4 ). This complex is composed of eight subunits termed COG1-COG8 that are organized into two "lobes": lobe A composed of COG1-COG4 and lobe B composed of COG5-COG8. 127 Variants in seven of the eight genes that encode these subunits all result in some form of congenital Variants in TRAPPC11 are linked to muscular disorders including
LGMD2S, CMD and generalized myopathy. This is supported by the elevated levels of CK in these individuals. In addition, cataracts and liver involvement have also been reported in some of these individuals. All of the above phenotypes are TRAPPC11-specific. A link between muscular defects and eye involvement is known, particularly for dystroglycanopathies. 114 Regarding the liver pathology, it has been shown that TRAPPC11 is involved in lipid-linked oligosaccharide synthesis and upregulation of the UPR. 105 This function of TRAPPC11 is unique and was not observed for other components of the TRAPP complex. The TRAPPC11-induced UPR includes upregulation of the transcription factor ATF6, overexpression of which is known to result in fatty liver. 128 Thus, some of the clinical manifestations of TRAPPC2L and TRAPPC6 (see Table 3 ), and may be related to the function of TRAPPC11 within the TRAPP complex and its role in membrane traffic. The main phenotypes observed in individuals with TRAPPC12 variants are encephalopathy and microcephaly. Although TRAPPC12 is unique amongst other TRAPP proteins with a role in mitosis through the kinetochore protein CENP-E, 121 and CENP-E variants also result in microcephaly, 129 given the overlap with clinical phenotypes seen for other TRAPP variants, it is likely that the clinical features of individuals with TRAPPC12 variants are also linked to its role within TRAPP.
| CONCLUSION
The burgeoning class of TRAPP-related disorders called TRAPPopathies will undoubtedly expand as whole exome sequencing continues to rise to prominence as a first-line diagnostic for new clinical disorders. As features of TRAPPopathies continue to be revealed, TRAPP genes will also start to be included in panel-specific sequencing as is commonly done for a number of disorders including muscular dystrophies. Indeed, given the common muscular phenotype in individuals with TRAPPC11 variants, it was recently suggested that TRAPPC11 be included in muscular dystrophy gene panels. 111 Understanding the common clinical features as well as the clinical differences will be an important goal in guiding clinicians toward treatments and researchers toward therapeutic targets and possible interventions. We apologize to all authors whose papers could not be cited in this review due to space limitations.
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